Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Milena Stain"'
Autor:
Julio Delgado, Caroline Voltz, Milena Stain, Ewa Balkowiec-Iskra, Brigitte Mueller, Johanna Wernsperger, Iwona Malinowska, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti
Publikováno v:
HemaSphere, Vol 5, Iss 8, p e616 (2021)
Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid thro
Externí odkaz:
https://doaj.org/article/a3006b67091a4eebbe6f6aaeeadc8c60
Autor:
Julio Delgado, Caroline Voltz, Milena Stain, Tuomo Lapveteläinen, Susanne Urach, Johanna Lähteenvuo, Karri Penttilä, Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti
Publikováno v:
HemaSphere, Vol 5, Iss 7, p e604 (2021)
Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs
Externí odkaz:
https://doaj.org/article/c1b190f2755848fa85807fd6f89529fa
Autor:
Harald Enzmann, Brigitte Mueller, Johanna Wernsperger, Iwona Malinowska, Christian Gisselbrecht, Ewa Balkowiec-Iskra, Caroline Voltz, Milena Stain, Francesco Pignatti, Julio Delgado
Publikováno v:
HemaSphere, Vol 5, Iss 8, p e616 (2021)
HemaSphere
HemaSphere
Luspatercept is a recombinant fusion protein that selectively binds to ligands belonging to the transforming growth factor-beta superfamily, resulting in erythroid maturation and differentiation. On June 25, 2020, a marketing authorization valid thro
Autor:
Karri Penttila, Susanne Urach, Milena Stain, Caroline Voltz, Christian Gisselbrecht, Tuomo Lapveteläinen, Johanna Lähteenvuo, Julio Delgado, Harald Enzmann, Francesco Pignatti
Publikováno v:
HemaSphere
HemaSphere, Vol 5, Iss 7, p e604 (2021)
HemaSphere, Vol 5, Iss 7, p e604 (2021)
Crizanlizumab is a monoclonal antibody that binds to P-selectin. On October 28, 2020, a conditional marketing authorization valid through the European Union (EU) was issued for crizanlizumab for the prevention of recurrent vaso-occlusive crises (VOCs
Autor:
Sandra Giannini, Paul A. Kyrle, Günter Christ, Milena Stain, Peter Quehenberger, Ansgar Weltermann, Christian Bieglmayer, Verena Schönauer
Publikováno v:
Thrombosis and Haemostasis. 89:837-841
SummaryHigh factor VIII (FVIII) is a risk factor for venous thromboembolism (VTE). The pathomechanism by which high FVIII leads to an increased risk of VTE is unknown. Physical activity and infusion of adrenalin provoke a rise in FVIII, which can be
Autor:
Milena Stain, Paul A. Kyrle, Klaus Lechner, Andreas Stümpflen, Christine Bialonczyk, Christine Mannhalter, Barbara Schneider, Erich Minar, Mirko Hirschl, S. Eichinger
Publikováno v:
Scopus-Elsevier
SummaryA G20210A transition in the prothrombin gene is a common risk factor of venous thrombosis. The risk of recurrent venous thrombo-embolism in carriers of the 20210A allele is unknown and guidelines for secondary thromboprophylaxis in these patie
Autor:
Mirko Hirschl, Erich Minar, Milena Stain, Sabine Eichinger, Paul A. Kyrle, Christine Bialonczyk, V. Schönauer, A. Weltermann
Publikováno v:
Journal of thrombosis and haemostasis : JTH. 3(12)
Summary. Background: The post-thrombotic syndrome (PTS) is a frequent complication of deep vein thrombosis (DVT). Patients with recurrent ipsilateral DVT have an increased risk of PTS; other risk factors are unknown. Objectives: To establish risk fac
Publikováno v:
Thrombosis research. 120(1)
Elevated lipoprotein (a) (Lp (a)) has been established as a risk factor of coronary heart disease and stroke. Findings concerning the risk of venous thromboembolism (VTE) in adults are contradictory. The aim of our study was to investigate, whether e
Autor:
Verena Gartner, Milena Stain, Mirko Hirschl, A. Weltermann, Erich Minar, Gregor Hron, Christine Bialonczyk, Sabine Eichinger, Paul A. Kyrle
Publikováno v:
The American journal of medicine. 119(1)
Purpose The relevance of a family history for venous thromboembolism with regard to the likelihood for recurrence is unknown. Subjects and methods We studied 826 patients for an average of 36 months after a first unprovoked venous thromboembolism and
Autor:
Barbara Schneider, S. Eichinger, Verena Schönauer, Erich Minar, Paul A. Kyrle, Ansgar Weltermann, Milena Stain
Publikováno v:
Archives of internal medicine. 164(1)
Background: In patients with a first symptomatic pulmonary embolism (PE), the risk of recurrence is unknown. We therefore investigated the risk of recurrence among patients with spontaneous symptomatic PE and among those with deep vein thrombosis (DV